Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Weili Zhao et al.|Journal of Hematology & Oncology|2017Cited by 256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Hang Su et al.|The Lancet Haematology|2019Cited by 248
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Bo Peng, Hang Su et al.|EBioMedicine|2020Cited by 41